Short Interest in Kazia Therapeutics Limited (NASDAQ:KZIA) Grows By 97.9%

Kazia Therapeutics Limited (NASDAQ:KZIA) saw a large growth in short interest in June. As of June 30th, there was short interest totalling 47,100 shares, a growth of 97.9% from the June 15th total of 23,800 shares. Based on an average daily volume of 6,870,000 shares, the short-interest ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $2.00 target price on shares of Kazia Therapeutics in a research report on Friday.

Institutional Investors Weigh In On Kazia Therapeutics

A hedge fund recently bought a new stake in Kazia Therapeutics stock. Platinum Investment Management Ltd. bought a new stake in Kazia Therapeutics Limited (NASDAQ:KZIA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,821,887 shares of the company’s stock, valued at approximately $801,000. Platinum Investment Management Ltd. owned about 11.15% of Kazia Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 30.89% of the company’s stock.

Kazia Therapeutics Price Performance

Shares of Kazia Therapeutics stock traded down $0.34 on Friday, hitting $0.90. The company’s stock had a trading volume of 25,340,895 shares, compared to its average volume of 5,788,863. Kazia Therapeutics has a 52-week low of $0.19 and a 52-week high of $1.58. The firm has a fifty day moving average price of $0.29 and a 200-day moving average price of $0.31.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.